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To commemorate World TB Day March 24th, 2017 The
International Journal of Infectious Diseases highlights the Advan-
ces, Challenges and Opportunities in the “End-TB” Era through
publishing 42 articles by a distinguished global authorship. The
series of articles review progress being made in achieving TB
control, reviews innovations in drugs, diagnostics, vaccines and
operational issues, and highlight remaining gaps and future
challenges that need to be overcome to achieve the ‘End TB’
targets. There is little doubt from current WHO morbidity and
mortality statistics,1 that TB is the most common infectious cause
of death worldwide; far surpassing both HIV and malaria.2 The
huge investments into HIV/AIDS and malaria have successfully
reduced morbidity and mortality rates from these infections.
2. Why is TB different from HIV and Malaria?
TB has speciﬁc features that complicate control efforts,
requiring unique and innovative approaches. These include the
poorly understood complex biology and pathogenesis of Mycobac-
terium tuberculosis infection, potential long latency periods,
unrecognized primary and re-infections, relatively asymptomatic
disease onset leading to transmission months before most patients
present for clinical care, a huge unrecognized reservoir of latent TB
infections compounded by a limited repertoire of cheap and safe
TB drugs, lengthy treatment with multiple drugs leading to poor
adherence. The growing and widespread problem of drug
resistance and major shortfalls in the available resources are
other important factors that distinguish TB from malaria and HIV.
3. Resources for TB control
The WHO's “End TB” strategy aims to reduce TB deaths by 95%,
reduce new cases by 90% between 2015 and 2035, and ensure that
no family is burdened with catastrophic expenses due to TB.3
However, this seems unrealistic to achieve in a situation where
over half a million cases of MDR TB occur every year, only 20% are
able to access appropriate care and treatment outcomes remain
sub-optimal.1,4 The mathematical model described by McBryde
et al. (2017),5 shows that MDR TB may sustain epidemic spread,6
even in the presence of some ﬁtness cost, and over time potentially
replace drug susceptible strains in the absence of effective MDR TB
control programs.5,6http://dx.doi.org/10.1016/j.ijid.2017.02.012
1201-9712/© 2017 The Authors. Published by Elsevier Ltd on behalf of International Soc
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Better utilization of resources, new diagnostics and affordable
drugs all need research to provide an informed platform for
rational use of available resources. However, research on TB is
underfunded; over 60 percent of available money for TB R&D
comes from public sources, and 65% of public money comes from a
single country, the United States.7 This is further emphasized by a
study from Cambodia showing that TB receives less funding there
compared to HIV and malaria, despite having a far bigger
population health impact.8
A critical review of the WHO's “End-TB” strategy concludes that
“if the End TB Strategy is to be successful in achieving TB
elimination,9 a more concerted action by funders and governments
will be required for further investments into TB prevention,
detection and treatment”.9 The proportion of HIV-infected patients
with TB inﬂuences the predictions and demonstrates the need for
close collaboration between TB and HIV programs.10 A limited
resource is negative-pressure isolation rooms. Present guidelines
are equivocal regarding when to de-isolate TB patients leading to
some patients being unnecessarily isolated for months, which is
associated with patient harm and occupies a scarce and expensive
resource.11
4. Tackling TB Co-morbidities with infectious and non-
communicable diseases
Co-infection with HIV greatly increases mortality and risk of
treatment failure,12 and diabetes mellitus also increases morbidity
and mortality of TB.13 These important co-morbidities clearly
demonstrate that TB management needs an integrated approach
and that every TB patient should be investigated for HIV and
diabetes, and every patient with HIV and diabetes should be
screened for active TB diseases and LTBI.
Following a cohort of 1696 TB patients in Tanzania, Nagu and
colleagues found that ART-näive TB/HIV patients had a seven-fold
mortality risk (RR = 7.42; 95% CI: 3.87, 14.22; p < 0.0001), whereas
TB/HIV patients on ART had a ﬁve-fold mortality risk (RR = 4.78;
95% CI: 2.41, 9.49; p < 0.0001).12 The median time to death was
shortest among ART-näive TB/HIV patients (thirty-six days). A
thirty-day increase on ART duration associated with a 3% mortality
reduction (RR = 0.97; 95% CI: 0.95, 0.99; p < 0.02), independent of
CD4+ T lymphocyte count and ART regimen.12
Diabetes mellitus, DM, increases the risk of developing TB by
two to three fold and increases the risk of TB treatment failure,
relapse and death.13 Hypertension is an increasing problemiety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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previously published studies of an association between TB and
hypertension.14
A study from The Republic of Congo,15 highlights the impor-
tance of coordinating diagnostics and treatment of HIV and TB/HIV
and describes how TB control programs there operate as distinct
entities with separate case management plans and protocols. For
instance, HIV testing is not systematically performed among TB
patients and the actual prevalence of TB/HIV co-infection remains
unknown.
Latent TB infection remains a difﬁcult clinical and public health
issue and the risk factors for progressing from latent TB to
symptomatic disease are not fully understood except when the
patient is obviously immunocompromised by HIV-infection, by
immunosuppressive drugs including anti-TNF therapy, or by
regimens required post-transplant. Also strategies for treating
latent MDR TB are urgently needed.16
5. Public Health, Social and Operational Issues
An important challenge is how to reach marginalized groups
with increased risk of TB like residents of refugee camps and
migrants especially in low incidence countries, where infection
control is very difﬁcult.17 Co-morbidities like HIV, diabetes
mellitus, viral hepatitis and alcohol, drug and cigarette use,
psychological care are important components for optimal patient
management to ensure compliance.17
Informed approaches to surveillance and control require
reliable, quality controlled diagnostics especially on drug suscep-
tibility. The report by Alabi et al. describes the establishment of a
TB reference laboratory in Gabon offering diagnostics, culture,
susceptibility testing and molecular diagnostics.18
The challenge of MDR TB is highlighted by Migliori et al.,
reviewing the situation among migrants entering Europe.19 Over
a quarter of TB cases in the European Union and European
Economic Area (EU/EEA) are reported among foreign-born
individuals and about 25% of the global multidrug-resistant TB
(MDR-TB) cases are reported in the European Region, particularly
from the former Soviet Union countries.19 One aspect of this is the
importance of the stigma from receiving a diagnosis of TB, which
must be addressed to encourage contact with the health care
service.20
The Ebola virus disease, EVD, epidemic had profound impact
on the health care systems of the affected countries in West
Africa.21 The study reviewed the impact on BCG immunizations,
TB diagnosis and management in the affected countries.21 The
EVD epidemic no doubt increased TB morbidity and mortality,
and the likely impact will not be known for several years to come.
Under-ﬁve vaccinations for TB with BCG, were affected adversely
by the EVD epidemic. The EVD outbreak was a result of global
failure and represents yet another ‘wake-up call’ to the
international community and particularly to African govern-
ments.21
Development of qualiﬁed, knowledgeable health care staff is
important to assure quality and rational utilization of resources,
but few studies have addressed the impact of training in TB
management on the behavior of health care staff.22 Another review
addresses the quality of care that is routinely provided in both
public and private sectors. Quality TB care is patient-centric care
that is consistent with international standards, delivered in an
accessible, timely, safe, effective, efﬁcient and equitable manner.23
It is well known that prisons are hot-spots for TB transmission.
A study from India shows that the OR of being diagnosed with TB
was 6 in district prisons compared to central facilities; the OR was
5.2 in facilities with more than 500 inmates compared to facilities
with fewer than 500 inmates, and diagnostic facilities reduced therisk of TB with an OR of 0.5 compared to facilities without.24 Lack of
TB screening at admission to the prison increased the OR of
diagnosing TB to 2.7.24
Children are an important target group to reduce under-5
mortality and morbidity, as well as the pool of latent infection, in
TB endemic areas.25 Barriers to the provision of preventive therapy
in resource-limited settings include: 1) the perceived inability to
rule out active disease, 2) fear of creating drug resistance, 3) non-
implementation of existing guidelines in the absence of adequate
monitoring and 4) poor adherence with long preventive therapy
courses. Barriers to TB treatment include: 1) perceived diagnostic
difﬁculties, 2) non-availability of chest radiography, 3) young
children presenting to unprepared maternal and child health
(MCH) services and 4) the absence of child friendly drug
formulations.26
6. Molecular studies
A review by Yeboah-Manu and colleagues highlights that
Mycobacterium africanum is found primarily in West Africa and
seems to progress less frequently to clinical disease and may even
show lower transmissibility.27 This presents an opportunity to
improve current understanding of host-pathogen interactions, and
for the development and evaluation of diagnostics, host-directed
therapies, and vaccines for tuberculosis . M. africanum may also
have important differences in transmission, pathogenesis, and
host-pathogen interactions, which could affect the evaluation of TB
intervention tools (diagnostics and vaccines).27
The unequal geographical distribution and spread of Mycobac-
terium tuberculosis complex (MTBC) species means that individual
research ﬁndings from one country or region cannot be generalized
across the continent. Thus, generalizing data from previous and
ongoing research studies on MTBC may be inaccurate and
inappropriate. A major rethink is required regarding the design
and structure of future clinical trials of new interventions.
The potential challenges for using whole genome sequencing,
WGS, for studies of MDR and XDR are discussed by McNerney R
(2017),28 and studies of standardized protocols for DNA extraction
and sequencing are urgently needed. This would be the ﬁrst step
for the development of harmonized methods to analyze, report and
interpret molecular sequencing technologies to guide the devel-
opment of personalized therapeutic regimens leading to improved
patient outcomes.
7. Immunological studies
Intact immune responses to cytomegalovirus (CMV) and
Epstein-Barr virus (EBV) represent a biologically and clinically
relevant correlate of ‘immunological ﬁtness’ in humans. The study
reported by Nagu et al., 29 found that Increased cellular immune
responses to CMV and EBV antigens at the time of diagnosis of
pulmonary tuberculosis were associated with increased survival
after a standard six months anti-TB therapy.29 Thus an intact
immune responses to cytomegalovirus (CMV) and Epstein-Barr
virus (EBV) may be a predictors for treatment outcome.29 The
study by Valentini et al. showed that BCG immunization induced
antibodies against host proteins.30 How this aberrant immune
response modiﬁes the immune response to BCG needs further
study, but BCG is also used as immunotherapy in selected cases of
bladder cancer, indicating a positive but unspeciﬁc effect on the
immune response. The second study by Valentini et al. used
peptide arrays to dissect the epitope speciﬁc humoral immune
responses across the entire M. tuberculosis protein molecules.31 An
interesting ﬁnding was that patients from South America
recognized more peptides compared to patients from South Africa
(both groups HIV-negative).31 A study using peptide microarrays
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syndrome recognised 68 - 78% M. tuberculosis peptides once again
suggesting mycobacterial involvement in sarcoidosis.32
Using paleomicrobiology it is possible to study the evolution of
MTBC over the past ten millennia and its association with human
migration, providing new insight into the probable origin of the
different MTBC bacterial lineages.33
8. TB Treatment
Tiberi et al. describe the evolution in WHO TB classiﬁcations
(taking into account an independently proposed new classiﬁca-
tion) and recent changes in WHO guidance, while discussing the
differences among them, including the latest evidence on the ex-
group ﬁve drugs.34
Despite the large investment made in treating patients with
rifampin-resistant TB, the majority of these patients still receive
suboptimal therapy and achieve poor outcomes. A study that
reviewed data regarding the expected return on investment in
performing second-line DST for all patients with rifampicin-
resistant TB concluded that “incorporating second-line DST into
the routine care of all patients diagnosed with rifampin-resistant
TB on Xpert1 seems a justiﬁable investment to make”.35
Sotgiu et al. reviewed studies describing a 9 to 12-month
regimen for MDR-TB cases, known as the Bangladesh regimen.36
The protocol includes an initial phase of 4 to 6 months of
kanamycin, moxiﬂoxacin, prothionamide, clofazimine, pyrazina-
mide, high dose isoniazid and ethambutol followed by 5 months of
moxiﬂoxacin, clofazimine, pyrazinamide and ethambutol.36
There is an unmet need for TB treatment trials recruiting
children and adolescents.37 Urgent questions address efﬁcacy,
toxicity and prophylactic treatment of contacts to MDR TB.37
A study from Tblisi, Georgia, described pulmonary surgery in
137 patients half with MDR/XDR TB.38 Whereas it was too early to
describe outcomes in terms of mortality, the study found that
“from the 98% of DS-TB cases presenting cavities or tuberculomas
and considered bacteriology cured according to WHO deﬁnitions,
56% were AFB positive from samples from the surgical specimens”.
Thus surgery need to be revisited in patients with extensive
pulmonary lesions even those with bacterial cure or patients
where bacterial cure is not possible.38
The study by Hanna et al. reviewed seven project teams
developing ﬁrst-in-class translational and quantitative methodol-
ogies that aim to inform drug development decision-making dose
selection, trial design and safety assessments, to achieve shorter
and safer therapies for patients in need.39 These tools offer the
opportunity to evaluate multiple hypotheses and provide a means
to identify, quantify, and understand relevant sources of variability,
to optimize translation and clinical trial design.39
In recent years there has been renewed interest in the use of
natural products, due to the wide range of pharmacophores and a
high degree of stereochemistry, and therefore three-dimensional-
ity that natural products possess.40 Compound groups like the
phenazines (which include clofazimine), piperidines, mycins
(which include the rifampicins), quinolones (including the
ﬂuoquinolones and bedaquiline) and antimicrobial peptides
(teixobactin, sansanmycins, Cyclomarin A, ecumicin, griselimycin,
lariatins and trichoderins).40
A review of the literature on anti-PD-1/PD-L1 therapy based on
the use in cancer therapy, indicate that anti-PD-1/PD-L1 therapy41
may be of potential beneﬁt in chronic lung infections thus adding
another potential intervention to the growing portfolio of host-
directed therapies.419. Diagnostics and Biomarkers
The study by Heller et al describes a cross-sectional study
including 100 Malawian patients with a clinical indication for
ultrasound and reviewed the literature on point-of-care ultra-
sound (POCUS) in Sub-Saharan Africa.42 The study concludes that
“Ultrasonography has evolved as a highly sensitive and speciﬁc
imaging tool for diagnosing relevant conditions at the point of care
in immune-competent and immune- compromised patients”.42
Gambhir and colleagues review the different imaging modalities
available including, MRI, CT, ultrasonography and 18F-ﬂuorodeox-
yglucose (FDG) PET-CT for the diagnosis of extrapulmonary TB.43
A review of molecular diagnostics and typing of mycobacteria
using DNS extracted from slides suggests that the method may
have potential.44 New rapid diagnostics remain a priority, and
Yerlikaya et al.,45 describe the database curated by FIND and
partners on the development of a well-curated and user-friendly
TB biomarker database.45
Host biomarkers may provide a sensitive and speciﬁc approach
to detect subclinical manifestations of clinical or subclinical TB,
and transcriptomics allows inspection of tens of thousands of
variables (such as gene expression, protein or metabolite levels) in
one step.46 The ﬁrst attempts to reduce the number of transcripts
in transcriptomic proﬁling of TB shows that the information
contained in such large biosignatures is redundant, but more
speciﬁc signatures can be derived by a more selective approach.46
A suitable approach for new markers for early diagnosis is the
paper by Valentini et al.,30 describing the use of peptide arrays to
ﬁnd Mycobacterium speciﬁc antibodies. Serology has so far not
been regarded as a useful tool for TB diagnosis, but given that no
early diagnostic tool is available (quantiferon-release assays
cannot distinguish latent and active TB) this should be explored
further.
10. Vaccines
The age old Bacille Calmette–Guérin (BCG) vaccine offers only
limited protection against TB and a healthy pipeline of new TB
vaccines are under various stages of development and evaluation.
Kaufmann et al. reviewed new vaccine candidates for TB
including subunit, inactivated whole-cell and live mycobacterial
vaccines.47 Current testing procedures evaluate the potency of
new candidates in animal models by measuring the reduction of
the bacillary load in the lungs during the acute phase of the
infection. However, so far none of the candidates has been able to
prevent the establishment of infection. The main characteristics
of several laboratory animal models are reviewed, reﬂecting that
none are able to simulate all the characteristics of human
tuberculosis. Therefore, it is important to test new candidates in
several models in order to generate convincing evidence of
efﬁcacy, including better efﬁcacy than BCG in humans. It is also
important to use “in silico” and “ex vivo” models to better
understand experimental data and to replace or reﬁne experi-
mental animal models.48 Using a mouse model, one study showed
that immunizing with proteins involved in cell wall biosynthesis
induced a better protection against aerosol challenge compared
to BCG even without an adjuvant.49
11. Tuberculosis and world literature
The historic literature overview provides an important remind-
er of the devastation that TB caused before effective treatment
became available.50 Mortality was high in all age groups, and often
patients were sick for many years with low quality of life. The
review warns us what the situation will look like if MDR and XDR-
TB are not brought under control.50
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Even though new drugs and treatment regimens are becoming
available, the cost remains prohibitive and responsible and optimal
introduction of these is required. The investments in TB are
insufﬁcient to reach the “End TB” goal, and the situation regarding
MDR and XDR TB is worsening. Bold political and funder
commitments, analogous to the ivermectin donation program
that helped to control onchocerciasis in West Africa in the 1980s,
are required. New, more effective drugs and innovations for
improving TB treatment outcomes are needed as well. A wide
range of host-directed therapies (HDT) require evaluation as
adjuncts to current TB drug treatment. Funders must take the bold
step of investing in novel concepts that challenge conventional
approaches and invest in evaluation of the efﬁcacy of the wide
range of HDTs available in randomized, placebo-controlled clinical
trials as adjuncts to current TB treatment regimens.
The need for recruiting, educating, and retaining health care
staff is highlighted, and the reviews also underline the importance
of integrating HIV and TB management programs15 and the
importance of diabetes mellitus as a TB co-morbidity.13 The report
that patients with apparent cure still had live Mycobacteria in
surgically removed tissue, underlines that better markers for cure
are badly needed and that surgery may be considered in patients
with persistent lesions after treatment for drug resistant TB, even
after apparent bacterial cure.
The current status quo is unacceptable. Among the many
problems include: no effective TB vaccine, the lengthy treatment
duration of TB, the high death rates associated with MDR/XDR TB,
the long term functional disability suffered by TB patients due to
permanent lung damage and the associated drug toxicities, the
neglect of childhood TB, the large burden of comorbidity with TB
and HIV or NCDs, and sparse affordable TB drug pipeline
The prospects of controlling TB and achieving the WHO ‘End TB
targets’ are daunting. It is clear that research funding allocated to
TB is substantially less than what is available for HIV and malaria.
This must change, given that TB remains the largest infectious
disease killer on the planet. Progress in HIV and malaria prevention
and management over the past three decades has demonstrated
that huge investments in research and control programs do pay
dividends.
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